INIS
adults
27%
antibodies
39%
clinical trials
19%
comparative evaluations
35%
coronaviruses
16%
corrections
16%
covid-19
23%
data
24%
diabetes mellitus
6%
diseases
16%
distribution
5%
doses
11%
durability
6%
evaluation
16%
failures
16%
hemagglutination
8%
humans
11%
hybrids
12%
hyperglycemia
6%
immunity
15%
influenza
16%
inhibition
8%
injuries
11%
kidneys
33%
laboratories
29%
leprosy
16%
management
8%
messenger-rna
21%
necrosis
5%
nuclear industry
33%
patients
100%
peaks
6%
performance
16%
presses
5%
protection
12%
regression analysis
5%
rickettsiae
7%
risks
19%
safety
22%
staphylococcus
8%
stars
28%
strains
13%
therapy
11%
thromboplastin
23%
transplants
16%
typhus
33%
vaccines
84%
values
12%
viruses
9%
Medicine and Dentistry
Acute Kidney Injury
8%
Acute Tubular Necrosis
8%
Antibody
5%
Avian Influenza
16%
Booster Dose
16%
Case Report
16%
Chickenpox Vaccine
12%
Chorea
12%
COVID-19
8%
Diagnosis
5%
Disease
16%
Endothelial Dysfunction
8%
Focal Segmental Glomerulosclerosis
16%
Hemagglutination Inhibiting Antibody
8%
Immunogenicity
33%
Infection
9%
Influenza A (H7N9)
16%
Influenza A Virus (H7N9)
12%
Kidney Injury
8%
Messenger RNA
8%
Mifamurtide
16%
Multibacillary Leprosy
16%
Murine Typhus
33%
Neutralizing Antibody
16%
Patient
31%
Randomized Clinical Trial
16%
Renal Failure
16%
Rickettsia typhi
11%
Rickettsiosis
8%
Severe Acute Respiratory Syndrome Coronavirus 2
16%
Therapeutic Procedure
5%
Typhus
5%
Uremia
8%
Keyphrases
Acute Kidney Injury
8%
Acute Tubular Necrosis
8%
Adjuvanted
10%
AS03
16%
BA.5
5%
Chorea
12%
Coagulation Analyzer
16%
COVID-19 Booster Vaccine
11%
Endothelial Dysfunction
8%
Febrile Illness
16%
Flea-borne Rickettsiosis
8%
Focal Segmental Glomerulosclerosis
16%
H7N9
6%
H7N9 Influenza Virus
16%
H7N9 Vaccine
16%
Hemagglutination Inhibition Antibody
6%
Hemichorea
16%
Immunogenicity
16%
Influenza A(H7N9)
6%
Kidney Injury
8%
Malassezia Pachydermatis
16%
MF59
13%
Multibacillary Leprosy
16%
Murine Typhus
33%
Portable Coagulometer
16%
Prerenal Azotemia
8%
Randomized Clinical Trial
16%
Renal Failure
16%
Rickettsia Typhi
11%
S Vaccine
11%
Short-term Durability
5%
Typhus Group
5%
Unusual Cause
8%
